Just a few years ago the outlook for treating patients with chronic hepatitis C...
Read More
Watch the Dr. Phil interview with Dr. Poordad
BARCELONA — Combination therapy with ABT-493, a novel NS3/4A protease inhibitor, and ABT-530, a...
BARCELONA — An investigational drug combination offers renewed hope of a cure for chronic...
BARCELONA — A new three-pronged approach to hepatitis C virus effectively treated prior non-responders...
BARCELONA — In this video perspective from the International Liver Congress, Fred Poordad, MD,...
– 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530...
AbbVie (NYSE: ABBV) announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis...
This edition contains the following: Frequently Asked Questions on Liver Disease Managing HCV-infected Patients...
This edition contains the following: Grazoprevir and Elbasvir Combination Therapy Portal Vein Thrombosis New...